Deciphera Pharmaceuticals Inc. — Sponsor Intelligence | 10 EU Trials

Filter these 10 trials by condition, phase, country and more.

Open in Search →

10 Registered trials

2 Recruiting

7 Completed trials

14 Countries active

9 Unique IMPs

100% Results reported

Phase III

Phase I/II

Phase I (Other)

Phase I (FiH)

Phase III: 4 Phase I/II: 1 Phase I (Other): 2 Phase I (FiH): 3

100%

7 of 7 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Gastrointestinal stromal tumour 3 Colony stimulating factor therapy 1 Non-small cell lung cancer 1 Myasthenia gravis 1 Giant cell tumour of tendon sheath 1

Top IMPs

RIPRETINIB 3 DCC-3116 2 SUNITINIB 2 VIMSELTINIB 2 DCC-3084 1 RITUXIMAB 1 SOTORASIB 1 TEMOZOLOMIDE 1 TIRABRUTINIB 1

All trials

10 total

Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) Pending

2025-523389-26-00 Phase III 8 countries RITUXIMAB; TEMOZOLOMIDE; TIRABRUTINIB
A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies Recruiting

2024-516476-15-00 Phase I/II 8 countries DCC-3116; RIPRETINIB
A Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) with Specific KIT Exon Mutations Who Were… Recruiting

2022-503058-37-00 Phase III 8 countries RIPRETINIB; SUNITINIB
A study to learn the effects of ripretinib (study drug) on how midazolam behaves in the body of people with advanced gastrointestinal stroma… Ended

2022-501477-40-00 Phase I (Other) 3 countries
This is a multicenter, randomized, Phase 3 study with vimseltinib or placebo in patients with Tenosynovial Giant Cell Tumor, consisting of 2… Ended

2024-513624-42-00 Phase III 7 countries VIMSELTINIB
A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients wit… Ended

2024-514933-39-00 Phase I (FiH) 5 countries VIMSELTINIB
A Phase 3 Study to compare how effective and safe DCC-2618 is versus sunitinib in patients with GIST who have been treated previously with i… Ended

2024-513277-52-00 Phase III 5 countries RIPRETINIB; SUNITINIB
A clinical trial to learn how an investigational drug (vimseltinib) is absorbed, distributed, broken down, and removed from the body when gi… Ended

2023-503415-15-00 Phase I (Other) 1 country
A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors Ended

2022-501474-19-00 Phase I (FiH) 4 countries DCC-3116; SOTORASIB
DCC-3084 monotherapy in patients with solid tumors Ended

2024-517829-12-00 Phase I (FiH) 3 countries DCC-3084

Showing 1–10 of 10 trials

← All sponsors A–Z